Focus on Immunizations

Back to articles

Meningococcal B vaccine: New recommendations for teens, young adults

KEY POINT

At CDC’s June 2015 Advisory Committee on Immunization Practice (ACIP) meeting, the ACIP Meningococcal Vaccines Work Group recommended that the decision to vaccinate adolescents and young adults against serogroup B meningococcal disease should be made at the individual level with health care providers. A serogroup B meningococcal vaccine series may be administered to patients 16–23 years of age, with the preferred vaccination age being 16–18 years of age.